TheStockDoctor

Following (0) Followers (0)

TheStockDoctor’s Activity

Sat Mar 16

Article Comment

TheStockDoctor commented on an article. 10:02 PM

16 Analysts Reveal Their Top 2 Stocks

This whole list is like an example of paranoia and how to not lose money. While it is important to preserve capital, I am tired of people without the guts to make a real call on a company that will make them some REAL money.

[more]

Sun Mar 3

CAPS Underperform Pitch Reply

TheStockDoctor commented on TMFBiologyFool's pitch for ARNA. 10:24 PM

After the flop of Qsymia, I doubt Belviq will experience the same fate. ARNA management has taken proactive steps to avoid the many pitfalls of Vivus. The risk-reward ratio is simply not there with ARNA. If the launch is slow, it might drop a dollar, [more]

CAPS Underperform Pitch

TheStockDoctor wrote about VIVUS, Inc. (VVUS) . 9:37 PM

VVUS Underperform

Qsymia was a total flop at initial release, and that is without any competition. As soon as Belviq hits the shelves, Qsymia sales will drop substantially.

Caps Pick

TheStockDoctor made a pick in CAPS. 9:37 PM

VIVUS, Inc. (VVUS) will Underperform the S&P 500

CAPS Outperform Pitch

TheStockDoctor wrote about Sarepta Therapeutics (SRPT) . 9:35 PM

SRPT Outperform

SRPT is about to breakout huge to the upside on accelerated approval status by the FDA. Initial projections of a patient population of only 300 is vastly underestimated as it is closer to 6,000.

Caps Pick

TheStockDoctor made a pick in CAPS. 9:35 PM

Sarepta Therapeutics (SRPT) will Outperform the S&P 500

CAPS Outperform Pitch

TheStockDoctor wrote about Arena Pharmaceuticals, Inc. (ARNA) . 9:32 PM

ARNA Outperform

ARNA stands poised on the edge of a major blockbuster diet drug that has the potential to hit the coveted billion dollar annual status.

Caps Pick

TheStockDoctor made a pick in CAPS. 9:32 PM

Arena Pharmaceuticals, Inc. (ARNA) will Outperform the S&P 500

CAPS Outperform Pitch

TheStockDoctor wrote about Aegerion Pharmaceuticals, Inc. (AEGR) . 9:02 PM

AEGR Outperform

With AEGR focused on an orphan drug with no alternative treatments available and only a single potential competitor that has significant side effects, AEGR becomes a compelling buy.

Caps Pick

TheStockDoctor made a pick in CAPS. 9:02 PM

Aegerion Pharmaceuticals, Inc. (AEGR) will Outperform the S&P 500

CAPS Stats & Trivia
CAPS Player Rating < 20
Player Rank 0 out of 75183
Score 0.00
Score Change Today 0
Accuracy 0.00%
Active Picks 4
Total Picks 4
Best Pick AEGR (+81.44)
Worst Pick VVUS (-16.76)
Average Score per Pick 0.00
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to TheStockDoctor’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show TheStockDoctor’s 10 Latest Posts